Mycobacterium haemophilum Infection after Alemtuzumab Treatment

Mycobacterium haemophilum Infection after Alemtuzumab Treatment

Bibliographic Details
Main Authors:	Mini Kamboj, Eddie Louie, Timothy Kiehn, Genovefa Papanicolaou, Michael Glickman, Kent Sepkowitz
Format:	Article
Language:	English
Published:	Centers for Disease Control and Prevention 2008-11-01
Series:	Emerging Infectious Diseases
Subjects:	M. haemophilum infectious complications alemtuzumab letter United States
Online Access:	https://wwwnc.cdc.gov/eid/article/14/11/07-1321_article

Similar Items

Mycobacterium haemophilum and Lymphadenitis in Immunocompetent Children, Israel
by: Yishai Haimi Cohen, et al.
Published: (2008-09-01)

Mycobacterium haemophilum and Lymphadenitis in Children
by: Lesla E.S. Bruijnesteijn van Coppenraet, et al.
Published: (2005-01-01)

Meningomyeloencephalitis secondary to Mycobacterium haemophilum infection in AIDS
by: Sandra Leskinen, et al.
Published: (2020-05-01)

Fatal disseminated Mycobacterium haemophilum infection involving the central nervous system in a renal transplant recipient
by: Marie Pacholec, et al.
Published: (2020-12-01)

Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review
by: Naruemit Sayabovorn, et al.
Published: (2021-01-01)

Mycobacterium haemophilum scleritis: two case reports and review of literature
by: Punyanuch Pisitpayat, et al.
Published: (2020-09-01)

Tattoo-associated Mycobacterium haemophilum Skin Infection in Immunocompetent Adult, 2009
by: Meagan K. Kay, et al.
Published: (2011-09-01)

Late-onset postoperative Mycobacterium haemophilum endophthalmitis masquerading as inflammatory uveitis: a case report
by: Warinyupa Pinitpuwadol, et al.
Published: (2018-02-01)

Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum
by: Pornboonya Nookeu, et al.
Published: (2019-09-01)

Mycobacterium haemophilum: A report of cutaneous infection in a patient with end-stage renal disease
by: Shahram Sabeti, et al.
Published: (2016-01-01)

Inclusion Body Myositis Treated with Alemtuzumab
by: Juliana Sá, et al.
Published: (2019-12-01)

Meccanismo d’azione dei farmaci più recenti, Teriflunomide e Alemtuzumab e implicazioni terapeutiche
by: Francesco Patti
Published: (2015-11-01)

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis
by: Trygve Holmøy, et al.
Published: (2019-08-01)

Rhodococcus equi Infection after Alemtuzumab Therapy for T-cell Prolymphocytic Leukemia
by: Jan J. Meeuse, et al.
Published: (2007-12-01)

Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis—Report of Two Cases
by: Daniela Rau, et al.
Published: (2015-06-01)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
by: Simona Rolla, et al.
Published: (2020-06-01)

Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses
by: Clara Hilger, et al.
Published: (2020-10-01)

Clinical efficacy and safety of alemtuzumab in postmarketing practice
by: N. V. Khachanova
Published: (2019-06-01)

Alemtuzumab-associated diffuse alveolar damage – a case report
by: Antonios Bayas, et al.
Published: (2020-09-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01)

The Role of Anti-Thymocyte Globulin or Alemtuzumab-Based Serotherapy in the Prophylaxis and Management of Graft-Versus-Host Disease
by: Robert Ali, et al.
Published: (2017-11-01)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
by: Jürgen Haas, et al.
Published: (2019-06-01)

Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis
by: Yeseul Kim, et al.
Published: (2018-10-01)

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
by: A. G. Vakrakou, et al.
Published: (2018-10-01)

Listeria monocytogenes infection associated with alemtuzumab – - a case for better preventive strategies
by: Trygve Holmøy, et al.
Published: (2017-04-01)

Low incidence of lymphoproliferative disease post kidney transplantation with prevalent use of alemtuzumab
by: John Fredy Nieto-Ríos, et al.
Published: (2014-01-01)

IMMUNE AND CYTOKINE STATUS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING ALEMTUZUMAB
by: M. N Khorobrykh, et al.
Published: (2014-07-01)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
by: Katja Akgün, et al.
Published: (2020-01-01)

Epidemiology of cervico-facial pediatric lymphadenitis as a result of nontuberculous mycobacteria
by: Enrico Tortoli
Published: (2012-01-01)

Alemtuzumab – nowy lek w terapii postaci rzutowej stwardnienia rozsianego. Pierwsza czy druga linia leczenia?
by: Jacek Zaborski
Published: (2015-11-01)

Highly active RRMS and ocrelizumab after failure of alemtuzumab therapy
by: Martin Vališ, et al.
Published: (2020-05-01)

Alemtuzumab-induced elimination of HIV-1-infected immune cells
by: Kiat Ruxrungtham, et al.
Published: (2016-01-01)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
by: Ester Riepl, et al.
Published: (2018-01-01)

Effect of Alemtuzumab on Intestinal Intraepithelial Lymphocytes and Intestinal Barrier Function in Cynomolgus Model
by: Lin-Lin Qu, et al.
Published: (2015-01-01)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
by: Wendy Gilmore, et al.
Published: (2020-06-01)

Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab
by: Paulette Esperanza Walo-Delgado, et al.
Published: (2021-10-01)

Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients
by: Martina Guthoff, et al.
Published: (2020-05-01)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
by: Tobias Ruck, et al.
Published: (2015-07-01)

Case Report: Adult Still’s Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient
by: Julia Krämer, et al.
Published: (2020-08-01)

Cannot write session to /tmp/vufind_sessions/sess_stpj3nfblihfjkqttqdjrl6lfv